James Davis

56PUBLICATIONS
170CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)ChiropracticGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (56)

|Oct 23, 2026
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium.

|Sep 24, 2026
Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

|Jul 02, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

|May 18, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Feb 27, 2026
Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis.

Benjamin Teruel, Ashley L Golbus, Elaine Park

Pageof 10

Frequent Collaborators

21 joint publications

Jack Khouri

17 joint publications

Surbhi Sidana

17 joint publications

Larry D Anderson

16 joint publications

Krina Patel